Download PDF
Thromb Haemost 1999; 81(03): 428-435
DOI: 10.1055/s-0037-1614490
Review Article
Schattauer GmbH

Comparison of the Effects of Apo(a) Kringle IV-10 and Plasminogen Kringles on the Interactions of Lipoprotein(a) with Regulatory Molecules

Song Xue
1   From The Scripps Research Institute, Department of Vascular Biology, USA
,
Michael A. Green
1   From The Scripps Research Institute, Department of Vascular Biology, USA
,
Philip V. LoGrasso   *
2   Novartis Pharmaceuticals Corporation, Summit, USA
,
Brian R. Boettcher
3   The Scripps Research Institute, Department of Vascular Biology La Jolla, CA, USA
,
Edwin L. Madison
1   From The Scripps Research Institute, Department of Vascular Biology, USA
,
Linda K. Curtiss
1   From The Scripps Research Institute, Department of Vascular Biology, USA
,
Lindsey A. Miles   *
1   From The Scripps Research Institute, Department of Vascular Biology, USA
› Author AffiliationsBlood drawing was performed in the General Clinical Research Center of Scripps Clinic, supported by NIH grant MOI RROO833. This is publication number 11071-VB from the Scripps Research Institute.
Further Information

Publication History

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Lipoprotein(a) [Lp(a)] is associated with atherosclerosis and with disease processes involving thrombosis. Lp(a) contains apoprotein (a) [apo(a)], which has a sequence highly homologous to plasminogen. Hence, Lp(a) binds directly to extracellular matrix, cellular plasminogen receptors and fibrin(ogen) and competes for the binding of plasminogen to these regulatory surfaces. These interactions may contribute to the proatherothrombogenic consequences of high Lp(a) levels. These interactions are mediated by lysine binding sites (LBS). Therefore, we examined the role of apo(a) kringle IV-10 [the only apo(a) kringle demonstrated to exhibit lysine binding activity in the intact lipoprotein] in the interaction of Lp(a) with these regulatory molecules. We have compared directly apo(a) KIV-10 with plasminogen K4 to examine whether these highly structurally homologous kringle modules are also functionally homologous. Futhermore, because the plasminogen K5-protease domain (K5-PD) binds directly to fibrin, we have also examined the ability of this plasminogen fragment to inhibit the interaction of Lp(a) with these regulatory molecules and with extracellular matrix. Apo(a) KIV-10 competed effectively for the binding of 125I-Lp(a) to these surfaces but was less effective than either intact Lp(a), plasminogen K4 or plasminogen. Plasminogen K5-PD was a better competitor than apo(a) KIV-10 for 125I-Lp(a) binding to the representative extra-cellular matrix, Matrigel, and to plasmin-treated fibrinogen. In contrast, plasminogen K5-PD did not compete for the interaction of Lp(a) with cells, although it effectively competed for plasminogen binding. These results suggest that Lp(a) recognizes sites in all of the regulatory molecules that are also recognized by apo(a) KIV-10 and that Lp(a) recognizes sites in extracellular matrix and in plasmin-modified fibrinogen that also are recognized by plasminogen K5-PD. Thus, the interaction of Lp(a) with cells is clearly distinct from that with extracellular matrix and with plasmin-treated fibrinogen and the recognition sites within Lp(a) and plasminogen for these regulatory molecules are not identical.

Portions of this manuscript were presented at the 69th Meeting of the American Heart Association, New Orleans, LA 1996.

* Present address: Dr. LoGrasso, Department of Molecular Design and Diversity, Merck Research Laboratories, Rahway, NJ 07065, USA


* This work was supported in part by The National Institute of Health, Grant #’s HL38272, HL45934 and HL31950 and by the American Heart Grant-In-Aid #9650636N. Dr. Xue is the recipient of an Individual National Research Service Award grant #HL09721.


 

  • References

  • 1 Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672-9.
    CrossrefPubMedGoogle Scholar
  • 2 Nordestgaard BG. The vascular endothelial barrier-selective retention of lipoproteins. Current Opinion In Lipidology 1996; 7: 269-73.
    CrossrefPubMedGoogle Scholar
  • 3 Simionescu M, Simionescu N. Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. FASEB Journal 1993; 7: 1359-66.
    CrossrefPubMedGoogle Scholar
  • 4 Camejo G, Hurt-camejo E, Olsson U, Bondjers G. Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipid 1993; 4: 385-91.
    CrossrefPubMedGoogle Scholar
  • 5 Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipo-protein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. Journal of Biological Chemistry 1984; 259: 11470-8.
    PubMedGoogle Scholar
  • 6 McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
    CrossrefPubMedGoogle Scholar
  • 7 Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, Lawn RM, Scanu AM. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proceedings of the National Academy of Sciences of the United States of America 1987; 84: 3224-8.
    CrossrefPubMedGoogle Scholar
  • 8 Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. Journal of Biological Chemistry 1983; 258: 4249-56.
    PubMedGoogle Scholar
  • 9 Wiman B, Wallen P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thrombosis Research 1977; 10: 213-22.
    CrossrefPubMedGoogle Scholar
  • 10 Whitaker AN, Rowe EA, Masci PP, Joe F, Gaffney PJ. The binding of glu- and lyS-plasminogens to fibrin and their subsequent effects on fibrinolysis. Thrombosis Research 1980; 19: 381-91.
    CrossrefPubMedGoogle Scholar
  • 11 Garman AJ, Smith RA. The binding of plasminogen to fibrin: evidence for plasminogen-bridging. Thrombosis Research 1982; 27: 311-20.
    CrossrefPubMedGoogle Scholar
  • 12 Knudsen BS, Silverstein RL, Leung LL, Harpel PC, Nachman RL. Binding of plasminogen to extracellular matrix. Journal of Biological Chemistry 1986; 261: 10765-71.
    PubMedGoogle Scholar
  • 13 Kelm RJ, Swords NA, Orfeo T, Mann KG. A plasminogen-osteonectin-collagen complex. Journal of Biological Chemistry 1994; 269: 30147-53.
    PubMedGoogle Scholar
  • 14 Miles L, Sebald MT, Fless GM, Scanu AM, Curtiss LK, Plow EF, Hoover-Plow JL. Interaction of Lipoprotein (a) with the Extracellular Matrix. Fibrinolyiss and Proteolysis 1998; 12: 79-83.
    PubMedGoogle Scholar
  • 15 Salonen EM, Zitting A, Vaheri A. Laminin interacts with plasminogen and its tissue-type activator. FEBS Letters 1984; 172: 29-32.
    CrossrefPubMedGoogle Scholar
  • 16 Salonen EM, Saksela O, Vartio T, Vaheri A, Nielsen LS, Zeuthen J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. Journal of Biological Chemistry 1985; 260: 12302-7.
    PubMedGoogle Scholar
  • 17 Stack MS, Moser TL, Pizzo SV. Binding of human plasminogen to basement-membrane (type IV) collagen. Biochemical Journal 1992; 284: 103-108.
    CrossrefPubMedGoogle Scholar
  • 18 Berglund L, Petersen TE. The gene structure of tetranectin, a plasminogen binding protein. Febs Letters 1992; 309: 15-9.
    CrossrefPubMedGoogle Scholar
  • 19 Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. Journal of Cell Biology 1986; 103: 2411-20.
    CrossrefPubMedGoogle Scholar
  • 20 Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemost 1991; 66: 32-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. Journal of Biological Chemistry 1985; 260: 4303-11.
    PubMedGoogle Scholar
  • 22 Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-5.
    CrossrefPubMedGoogle Scholar
  • 23 Rouy D, Koschinsky ML, Fleury V, Chapman J, Angles CE. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31: 6333-9.
    CrossrefPubMedGoogle Scholar
  • 24 Gonzalez-Gronow M, Edelberg J, Pizzo S. Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 1989; 28: 2374-7.
    CrossrefPubMedGoogle Scholar
  • 25 Miles LA, Fless GM, Scanu AM, Baynham P, Sebald MT, Skocir P, Curtiss LK, Levin EG, Hoover PJ, Plow EF. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 1995; 73: 458-65.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 3847-51.
    CrossrefPubMedGoogle Scholar
  • 27 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-3.
    CrossrefPubMedGoogle Scholar
  • 28 Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
    CrossrefPubMedGoogle Scholar
  • 29 Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. 1993; Biochemistry 32: 4628-33.
    CrossrefPubMedGoogle Scholar
  • 30 Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO Journal 1989; 8: 4035-40.
    PubMedGoogle Scholar
  • 31 Vander-Hoek Y, Sangrar W, Cote GP, Kastelein JJ, Koschinsky ML. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arteriosclerosis & Thrombosis 1994; 14: 1792-8.
    CrossrefPubMedGoogle Scholar
  • 32 Kramer GA, Greiber S, Pavenstadt H, Quaschning T, Winkler K, Schollmeyer P, Wanner C. Interaction of native and oxidized lipoprotein(a) with human mesangial cells and matrix. Kidney International 1996; 49: 1250-61.
    CrossrefPubMedGoogle Scholar
  • 33 Pekelharing HL, Kleinveld HA, Duif PF, Bouma BN, van RH. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thrombosis & Haemostasis 1996; 75: 497-502.
    PubMedGoogle Scholar
  • 34 Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, Hoover PJ, Brunck T, Plow EF. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4(37). Journal of Clinical Investigation 1993; 91: 283-91.
    CrossrefPubMedGoogle Scholar
  • 35 Scanu AM, Pfaffinger D, Lee JC, Hinman J. A single point mutation (Trp72-Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochimica et Biophysica Acta 1994; 1227: 41-5.
    CrossrefPubMedGoogle Scholar
  • 36 Klezovitch O, Scanu AM. Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E coli and CHO cells. Arteriosclerosis, Thrombosis & Vascular Biology 1996; 16: 392-8.
    CrossrefPubMedGoogle Scholar
  • 37 Klezovitch O, Edelstein C, Scanu AM. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. Journal of Clinical Investigation 1996; 98: 185-91.
    CrossrefPubMedGoogle Scholar
  • 38 Ernst A, Helmhold M, Brunner C, Petho SA, Armstrong VW, Muller HJ. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). Journal of Biological Chemistry 1995; 270: 6227-34.
    CrossrefPubMedGoogle Scholar
  • 39 LoGrasso PV, Cornell KS, Boettcher BR. Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. Journal of Biological Chemistry 1994; 269: 21820-7.
    PubMedGoogle Scholar
  • 40 Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the lowry procedure to simplify protein determination in membrane and lipoprotein samples. Analytical Biochemistry 1978; 87: 206-10.
    CrossrefPubMedGoogle Scholar
  • 41 Shepherd J, Bedford DK, Morgan HG. Radioiodination of human low density lipoprotein: a comparison of four methods. Clinica Chimica Acta 1976; 66: 97-109.
    CrossrefPubMedGoogle Scholar
  • 42 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
    CrossrefPubMedGoogle Scholar
  • 43 Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. Journal of Biological Chemistry 1988; 26: 11928-34.
    PubMedGoogle Scholar
  • 44 Sottrup-Jesen L, Claeys H, Zajdel M, Petersen TE, Magnusson S. Progress in Chemical Fibrinolysis and Thrombolysis. 1978; 3: 191-209.
    PubMedGoogle Scholar
  • 45 Wallen P, Wiman B. Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochimica et Biophysica Acta 1972; 257: 122-34.
    CrossrefPubMedGoogle Scholar
  • 46 Nilsson T, Sjoholm I, Wiman B. Circular dichroism studies on alpha 2-antiplasmin and its interactions with plasmin and plasminogen. Biochimica et Biophysica Acta 1982; 705: 264-70.
    CrossrefPubMedGoogle Scholar
  • 47 Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Analytical Biochemistry 1980; 107: 220-39.
    CrossrefPubMedGoogle Scholar
  • 48 Thorsen S, Clemmensen I, Sottrup JL, Magnusson S. Adsorption to fibrin of native fragments of known primary structure from human plasminogen. Biochimica et Biophysica Acta 1981; 668: 377-87.
    CrossrefPubMedGoogle Scholar
  • 49 Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM. Modification of Apolipoprotein(a) Lysine Bnding Site Reduces Atherosclerosis in Transgenic Mice. Journal of Clinical Investigation 1997; 100: 558-64.
    CrossrefPubMedGoogle Scholar
  • 50 Scanu AM. Identification of mutations in human apolipoprotein(a) kringle 4-37 from the study of the DNA of peripheral blood lymphocytes: relevance to the role of lipoprotein(a) in atherothrombosis. American Journal of Cardiology 1995; 75: 588-618.
    PubMedGoogle Scholar
  • 50a Hoover-Plow J, Miles LA, Fless GM, Scanu AM, Plow EF. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry 1993; 32: 13681-7.
    CrossrefPubMedGoogle Scholar
  • 51 Castellino FJ, McCance SG. The Kringle domains of human plasminogen. Ciba Found Symp 1997; 212: 46-60.
    PubMedGoogle Scholar
  • 52 Christensen U. The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function. Biochem J 1984; 223 (02) 413-21.
    CrossrefPubMedGoogle Scholar
  • 53 Menhart N, McCance SG, Sehl LC, Castellino FJ. Functional independence of the kringle 4 and kringle 5 regions of human plasminogen. Biochemistry 1993; 32: 8799-806.
    CrossrefPubMedGoogle Scholar
  • 54 Huby T, Schroder W, Doucet C, Chapman J, Thillet J. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. Biochemistry 1995; 34: 7385-93.
    CrossrefPubMedGoogle Scholar
  • 55 Hughes SD, Ighani S, Verstuyft J, Rubin EM. Lipoprotein (a) vascular binding: in vivo analysis of the role of lysine binding sites using adenovirus mediated gene transfer. Circulation 1996; 94 38 Abs 211.
    PubMedGoogle Scholar